Evidence for Management of Small Cell Lung Cancer

Samson, David J; Seidenfeld, Jerome; Simon, George R.; Turrisi, Andrew T.; Bonnell, Claudia J; Ziegler, Kathleen M; Aronson, Naomi

doi:10.1378/chest.07-1384

Cited by 65 publications

(12 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCLC is a high-grade neuroendocrine malignancy which is very aggressive with extremely poor prognosis. Platinum-based chemotherapy and radiotherapy is the treatment of choice for limited-stage SCLC, while chemotherapy alone is used for extensive SCLC [7]. The overall 10-year survival rate is 5% [8,9].…”

Section: Introductionmentioning

confidence: 99%

Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors

Zheng

Ettinger²,

Maleki³

2013

Acta Cytologica

View full text Add to dashboard Cite

Background: Distinction of small cell lung carcinoma (SCLC) from non-small cell lung carcinoma (NSCLC) is critical because of the differences in prognosis and management. Patients with SCLC usually present with distant metastasis, and clinicians demand an accurate diagnosis in order to initiate appropriate therapy. Limited cytology material, occasionally with crush artifact, is not uncommon. Therefore, robust cytomorphologic features and a small immunostaining panel would be ideal to differentiate SCLC from NSCLC and other neuroendocrine neoplasms. We evaluated CD56 and the quantitative Ki-67 immunohistochemical panel in comparison to synaptophysin and chromogranin, along with cytomorphology to diagnose SCLC. Design: Eighty-eight cases of SCLC were retrieved from the cytology archives of The Johns Hopkins Hospital. Forty neuroendocrine neoplasms were used as control cases. Results: SCLCs included 33 lung cases and 55 metastatic lesions. The specimens were obtained by fine needle aspiration, thoracocentesis, bronchoalveolar lavage and abdominal paracentesis. CD56 was expressed in 98.9% of SCLCs, which is significantly more sensitive than synaptophysin and chromogranin. The Ki-67 labeling index was high (>70%) in all cases, which is a reliable marker to differentiate SCLC from other neuroendocrine neoplasms and NSCLC. Conclusion: CD56 and quantitative Ki-67 along with cytomorphology is a robust immunohistochemical panel to differentiate SCLC from other neuroendocrine neoplasms and NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors

Zheng

Ettinger²,

Maleki³

2013

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…[457] This reassignment has wide implications on therapeutic strategies because initial randomized data are in favor of using RT over surgery combined with CHT as first-line treatment. However, recent studies have shown a reasonable survival rate in patients who underwent surgery plus CHT as curative-intent therapy for VLD-stage SCLC.…”

Section: Discussionmentioning

confidence: 99%

“…[10] Notwithstanding, current evidence-based clinical guidelines have no conclusion on surgery as first-line treatment in cases of VLD-stage SCLC. [5] However, surgeons will undoubtedly continue to offer surgery to T1-T2N0 patients although remains controversial. [11]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relevance of an incidental chest finding

Cortés-Télles¹,

Mendoza²

2012

Lung India

View full text Add to dashboard Cite

Solitary pulmonary nodule represents 0.2% of incidental findings in routine chest X-ray images. One of the main diagnoses includes lung cancer in which small-cell subtype has a poor survival rate. Recently, a new classification has been proposed including the very limited disease stage (VLD stage) or T1-T2N0M0 with better survival rate, specifically in those patients who are treated with surgery. However, current recommendations postulate that surgery remains controversial as a first-line treatment in this stage. We present the case of a 46-year-old female referred to our hospital with a preoperative diagnosis of a solitary pulmonary nodule. On initial approach, a biopsy revealed a small cell lung cancer. She received multimodal therapy with surgery, chemotherapy, and prophylactic cranial irradiation and is currently alive without recurrence on a 2-year follow-up.

show abstract

“…While the efficacy of viscosupplementation has been well supported in the literature, the reader must view the magnitude of effectiveness with some degree of skepticism because of limitations presented by low trial quality and publication bias 19,25. For example, the authors of a 2009 Cochrane review3 reported that viscosupplementation is an effective treatment for knee OA, with beneficial effects on pain, function, and patient global assessment, especially at the 5- to 13-week period.…”

Section: Efficacymentioning

confidence: 99%

Long term safety, efficacy, and patient acceptability of hyaluronic acid injection in patients with painful osteoarthritis of the knee

McArthur¹,

Dy²,

Fabricant³

et al. 2012

PPA

View full text Add to dashboard Cite

The increasing prevalence of painful knee osteoarthritis has created an additional demand for pharmacologic management to prevent or delay surgical management. Viscosupplementation, via intraarticular injection of hyaluronic acid (HA), aims to restore the favorable milieu present in the nonarthritic joint. The safety profile of intraarticular HA injections for painful knee osteoarthritis is well established, with the most common adverse effect being a self-limited reaction at the injection site. Although acceptance of the early literature has been limited by publication bias and poor study quality, more recent and rigorous meta-analysis suggests that intraarticular HA injection is superior to placebo injection for pain relief and matches, if not surpasses, the effect size of other nonoperative treatments, such as nonsteroidal anti-inflammatory medication. Intraarticular HA injection is effective in providing temporary pain relief in patients with painful knee osteoarthritis. Future investigations should focus on optimizing the composition and administration of HA agents to provide prolonged relief of painful osteoarthritis in the knee and other joints.

show abstract

Evidence for Management of Small Cell Lung Cancer

Cited by 65 publications

References 68 publications

Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors

Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors

Relevance of an incidental chest finding

Long term safety, efficacy, and patient acceptability of hyaluronic acid injection in patients with painful osteoarthritis of the knee

Contact Info

Product

Resources

About